Importantly, phase 2a randomized placebo-controlled study of anti-IL-33 in peanut-induced allergy suggests that a single dose of Etokimab, IL-33 blocker, could reduce atopy-related adverse effecs. The gene discussed is IL33; the disease is Allergy.